Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Premarket Safety Plan Is Not Cost-Effective Rx Development – PhRMA

Executive Summary

Safety requirements outlined in FDA's "Premarketing Risk Assessment" concept paper seem to run counter to Commissioner McClellan's emphasis on cost-effective drug development, the Pharmaceutical Research & Manufacturers of America said during a public workshop on risk management April 9

You may also be interested in...



Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says

Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9

Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says

Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9

Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says

Drug and biologic sponsors should conduct a risk assessment on the product's name, labeling and packaging to minimize medication errors, an FDA concept paper states

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel